Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esmethadone (Primary)
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Acronyms RELIANCE I
Sponsors Relmada Therapeutics

Most Recent Events

18 Jun 2024 According to a Relmada Therapeutics Media Release, REL-1017 clinical data from the Reliance I Study were published in The Journal of Clinical Psychiatry.
18 Jun 2024 Results presented in a Relmada Therapeutics Media Release
20 Sep 2023 Results presented in a Relmada Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com